CRISPR Therapeutics AG — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
CRISPR reported Q2 2026 CASGEVY revenue of $76M (78% QoQ, 151% YoY growth). FDA approved CASGEVY for children as young as 2 years with SCD/TDT on Aug 3, 2026—53 days post-filing—expanding eligible patient pool by ~5,500. Cash position increased to $2.36B (from $1.98B Dec 31, 2025) via $585.4M convertible note issuance in March 2026. Net loss improved to $91.2M (Q2 2026) vs. $208.5M (Q2 2025). CTX340 and CTX460 Phase 1 trials initiated; CTX310 Phase 1b ongoing. Collaboration profit-share with Vertex remains 40/60 CRISPR/Vertex on CASGEVY.
Why this rating
Strong CASGEVY revenue growth (151% YoY, now $76M/qtr) is material to ~$4.1B market-cap biotech. Pediatric approval materially expands addressable market and validates platform. Early-stage pipeline progression (3 new in vivo programs) demonstrates execution. 56% net loss reduction YoY shows path toward profitability. Not yet transformational but significant near-term momentum.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.